Parstatin Suppresses Ocular Neovascularization and Inflammation | Zendy

Huang Hu | Zendy; Panagiotis Vasilakis | Zendy; Xiufeng Zhong | Zendy; JiKui Shen | Zendy; Katerina Geronatsiou | Zendy; Helen Papadaki | Zendy; Michael E. Maragoudakis | Zendy; Sotirios P. Gartaganis | Zendy; Stanley A. Vinores | Zendy; Nikos E. Tsopanoglou | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Parstatin Suppresses Ocular Neovascularization and Inflammation

Author(s) -

Huang Hu,

Panagiotis Vasilakis,

Xiufeng Zhong,

JiKui Shen,

Katerina Geronatsiou,

Helen Papadaki,

Michael E. Maragoudakis,

Sotirios P. Gartaganis,

Stanley A. Vinores,

Nikos E. Tsopanoglou

Publication year - 2010

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.10-5576

Subject(s) - neovascularization , corneal neovascularization , leukostasis , angiogenesis , retinal , inflammation , medicine , pharmacology , choroidal neovascularization , chemistry , ophthalmology , immunology

Parstatin is a 41-mer peptide formed by proteolytic cleavage on activation of the PAR1 receptor. The authors recently showed that parstatin is a potent inhibitor of angiogenesis. The purpose of the present study was to evaluate the therapeutic effect of parstatin on ocular neovascularization.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research